Who Paid My Doc
David Lucas
Neuromusculoskeletal Medicine, Sports Medicine Clermont, FL Medical Doctor
NPI 1336131069 CMS profile 151444
2020 Oakley Seaver Dr, Clermont, FL 34711
General payments
$3,683
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, David Lucas of Clermont, FL is reported in the CMS Open Payments database as having received $3,683 across 29 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 87th percentile of Neuromusculoskeletal Medicine, Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $244 | 4 | |
| 2024 | General | $68 | 3 | |
| 2023 | General | $16 | 1 | |
| 2022 | General | $185 | 6 | |
| 2021 | General | $93 | 3 | |
| 2020 | General | $2,822 | 3 | |
| 2019 | General | $255 | 9 |
Beside peers
- David Lucas
- Neuromusculoskeletal Medicine, Sports Medicine median
- Middle half of Neuromusculoskeletal Medicine, Sports Medicine
- National median
In program year 2025, general payments to David Lucas were reported at $244. Among 69 Neuromusculoskeletal Medicine, Sports Medicine profiles paid that year, the median was $125 and the middle half received between $37 and $473.
Show as a table
| Year | David Lucas | Neuromusculoskeletal Medicine, Sports Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $255 | $152 | $43–$474 | $163 |
| 2020 | $2,822 | $113 | $31–$725 | $114 |
| 2021 | $93 | $167 | $50–$469 | $132 |
| 2022 | $185 | $132 | $46–$572 | $149 |
| 2023 | $16 | $109 | $39–$366 | $160 |
| 2024 | $68 | $115 | $37–$321 | $164 |
| 2025 | $244 | $125 | $37–$473 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 9 drugsPart D claims
366
Drug cost
$1,546
Branded share of claims
27%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 79 | $425 | |
| Erythromycin Erythromycin Base | Brand | 20 | $390 | |
| Amoxicillin | Generic | 138 | $192 | |
| Methylprednisolone | Generic | 18 | $134 | |
| Prednisone | Generic | 39 | $105 | |
| Celecoxib | Generic | 13 | $103 | |
| Meloxicam | Generic | 19 | $93 | |
| Oxycodone Hcl | Generic | 20 | $60 | |
| Tramadol Hcl | Generic | 20 | $43 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 38 billing codesPaid by Medicare
$122,794
Medicare patients
399
Services billed
16,569
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Ischemic heart disease | 38% | |
| Chronic kidney disease | 38% | |
| Diabetes | 32% | |
| Depression | 27% | |
| Atrial fibrillation | 26% | |
| Heart failure | 22% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose J7324 | Office | 13 | 43 | $4,019 |
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 130 | 14,790 | $1,486 |
| Injection, methylprednisolone acetate, 40 mg J1030 | Office | 81 | 177 | $503 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
29 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Neuromusculoskeletal Medicine, Sports Medicine in Florida
Qahtan Abdulfattah
Neuromusculoskeletal Medicine, Sports Medicine · Brooksville, FL
Kevin Nowicki
Neuromusculoskeletal Medicine, Sports Medicine · Clermont, FL
Raymond Weiand
Neuromusculoskeletal Medicine, Sports Medicine · Palm Coast, FL
Larry Fishman
Neuromusculoskeletal Medicine, Sports Medicine · Brandon, FL
Raul Correa
Neuromusculoskeletal Medicine, Sports Medicine · Bradenton, FL
Stephen Wood
Neuromusculoskeletal Medicine, Sports Medicine · Largo, FL
Related records
Neuromusculoskeletal Medicine, Sports Medicine in Florida
Practitioners in the same specialty and state, ranked by reported value.
All Neuromusculoskeletal Medicine, Sports Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Florida
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.